Efficacy and Safety of Adalimumab in Patients With Active Uveitis

Summary

A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.

Timeline

Start

2010-08

Primary completion

2014-07

Completion

2014-08

Outcome

Met primary endpoint

release “The VISUAL-I study found that compared to placebo, patients on HUMIRA were less likely to experience treatment failure (TF)” abbvie.com ↗

release “The VISUAL-I study found that compared to placebo, patients on HUMIRA were less likely to experience TF (hazard ratio=0.5; 95 percent CI, 0.36–0.70; P<0.001)” abbvie.com ↗

Publications

• Results Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.
• Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017 Jun 1;135(6):511-518. doi: 10.1001/jamaophthalmol.2017.0603.
• Grewal DS, O'Sullivan ML, Kron M, Jaffe GJ. Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular Edema. Am J Ophthalmol. 2017 May;177:116-125. doi: 10.1016/j.ajo.2017.02.017. Epub 2017 Feb 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	Subcutaneous
Background	Prednisone	Other / unclassified	60 mg	Oral

Indications